BridgeBio Oncology Therapeutics (BBOT) vs Atrium Therapeutics (RNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Atrium Therapeutics is the larger company by market cap ($149.3 million vs $145.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBOT | RNA |
|---|---|---|
| Share price | $1.81 | $6.92 |
| Market cap | $145.25M | $149.27M |
| 1-day change | -2.69% | -0.86% |
| YTD return | -85.54% | — |
| 1-year return | -85.39% | — |
| P/E ratio (TTM) | 3.42 | — |
| EPS (TTM) | $0.53 | $-5.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-134.04M | — |
| 52-week high | $14.87 | $16.77 |
| 52-week low | $1.79 | $6.36 |
| Distance from 52-week high | -87.83% | -58.74% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1060.22% | +217.92% |
| Average volume | 631.56K | 297.20K |
| Shares outstanding | 80.25M | 21.57M |
| Employees | 92 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About BridgeBio Oncology Therapeutics
BBOT stock →BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About Atrium Therapeutics
RNA stock →Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy.
Health Care · Biotechnology: Pharmaceutical Preparations
BBOT vs RNA FAQ
Which is bigger, BridgeBio Oncology Therapeutics or Atrium Therapeutics?
Atrium Therapeutics (RNA) is larger, with a market capitalization of $149.27M compared with $145.25M for BridgeBio Oncology Therapeutics (BBOT).
Are BridgeBio Oncology Therapeutics and Atrium Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.